Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

UVaDOC. Repositorio Documental de la Universidad de Valladolid
Publicación Artículo científico (JournalArticle)

Spherical means-based free-water volume fraction from diffusion MRI increases non-linearly with age in the white matter of the healthy human brain

  • Pieciak, Tomász
  • París I Brandrés, Guillem Lluis
  • Beck, Dani
  • Maximov, Ivan I.
  • Tristán Vega, Antonio
  • Luis García, Rodrigo de
  • Westlye, Lars T.
  • Aja Fernández, Santiago
Producción Científica, The term free-water volume fraction (FWVF) refers to the signal fraction that could be found as the cerebrospinal fluid of the brain, which has been demonstrated as a sensitive measure that correlates with cognitive performance and various neuropathological processes. It can be quantified by properly fitting the isotropic component of the magnetic resonance (MR) signal in diffusion-sensitized sequences. Using healthy subjects (178F/109M) aged 25-94, this study examines in detail the evolution of the FWVF obtained with the spherical means technique from multi-shell acquisitions in the human brain white matter across the adult lifespan, which has been previously reported to exhibit a positive trend when estimated from single-shell data using the bi-tensor signal representation. We found evidence of a noticeably non-linear gain after the sixth decade of life, with a region-specific variate and varying change rate of the spherical means-based multi-shell FWVF parameter with age, at the same time, a heteroskedastic pattern across the adult lifespan is suggested. On the other hand, the FW corrected diffusion tensor imaging (DTI) leads to a region-dependent flattened age-related evolution of the mean diffusivity (MD) and fractional anisotropy (FA), along with a considerable reduction in their variability, as compared to the studies conducted over the standard (single-component) DTI. This way, our study provides a new perspective on the trajectory-based assessment of the brain and explains the conceivable reason for the variations observed in FA and MD parameters across the lifespan with previous studies under the standard diffusion tensor imaging., Ministerio de Ciencia e Innovación (MCIN-AEI) y FEDER-UE (grant PID2021-124407NB-I00), Ministerio de Ciencia e Innovación (MCIN-AEI) - Unión Europea “NextGenerationEU/PRTR” (grant TED2021-130758B-I00), Ministry of Science and Higher Education (Poland) - Bekker programme (grant PPN/BEK/2019/1/00421), Norwegian ExtraFoundation for Health and Rehabilitation (2015/FO5146), European Union's Horizon 2020 research and Innovation program (ERC 802998)
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Large-scale analysis of structural brain asymmetries in schizophrenia via the ENIGMA consortium

  • Schijven, Dick
  • Postema, Merel C.
  • Fukunaga, Masaki
  • Tordesillas-Gutiérrez, Diana
  • Crespo-Facorro, Benedicto
  • Francks, Clyde
ENIGMA consortium: et al., Left-right asymmetry is an important organizing feature of the healthy brain that may be altered in schizophrenia, but most studies have used relatively small samples and heterogeneous approaches, resulting in equivocal findings. We carried out the largest case-control study of structural brain asymmetries in schizophrenia, with MRI data from 5,080 affected individuals and 6,015 controls across 46 datasets, using a single image analysis protocol. Asymmetry indexes were calculated for global and regional cortical thickness, surface area, and subcortical volume measures. Differences of asymmetry were calculated between affected individuals and controls per dataset, and effect sizes were meta-analyzed across datasets. Small average case-control differences were observed for thickness asymmetries of the rostral anterior cingulate and the middle temporal gyrus, both driven by thinner left-hemispheric cortices in schizophrenia. Analyses of these asymmetries with respect to the use of antipsychotic medication and other clinical variables did not show any significant associations. Assessment of age- and sex-specific effects revealed a stronger average leftward asymmetry of pallidum volume between older cases and controls. Case-control differences in a multivariate context were assessed in a subset of the data (N = 2,029), which revealed that 7% of the variance across all structural asymmetries was explained by case-control status. Subtle case-control differences of brain macrostructural asymmetry may reflect differences at the molecular, cytoarchitectonic, or circuit levels that have functional relevance for the disorder. Reduced left middle temporal cortical thickness is consistent with altered left-hemisphere language network organization in schizophrenia., The ENIGMA project is in part supported by the National Institute of Biomedical Imaging and Bioengineering of the NIH (U54EB020403). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. Individual Funding Sources: D.S., M.C.P., S.E.F., and C.F.: Max Planck Society (Germany). R.A.-A.: Miguel Servet contract from the Carlos III Health Institute (CP18/00003). J.V.-B.: Instituto de Investigación Sanitaria Valdecilla (IDIVAL) (INT/A21/10, INT/A20/04). D.A.: South-Eastern Norway Regional Health Authority (2019107, 2020086). L.T.W.: Research Council of Norway (223273, 300767), South-Eastern Norway Regional Health Authority (2019101), and European Research Council under the European Union’s Horizon 2020 Research and Innovation Program (ERC StG, 802998). O.A.A.: Research Council of Norway (223273, 275054), KG Jebsen Stiftelsen, South East Norway Health Authority (2017-112, 2019-108). P.K.: NIH (R01MH123163, R01EB015611). M.J.G.: National Health and Medical Research Council (NHMRC) (630471, 1051672, 1081603). C.P.: NHMRC Senior Principal Research Fellowship (1105825), NHMRC L3 Investigator Grant (1196508). V.D.C.: NIH (R01MH118695), NSF (2112455). J.M.F.: Senior Research Career Scientist Award, Department of Veterans Affairs. P.F.-C.: Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Instituto de Salud Carlos III, cofunded by European Union (European Regional Development Fund (ERDF)/European Social Fund (ESF), “Investing in your future”): Sara Borrell Research contract (CD19/00149). G.S.: Italian Ministry of Health (RC17-18-19-20-21/A). A.N.V.: National Institute of Mental Health (NIMH), Canadian Institutes of Health Research (CIHR), Canada Foundation for Innovation, Centre for Addiction and Mental Health (CAMH) Foundation, University of Toronto. Y.-C.C.: Korean Mental Health Technology R&D Project (HL19C0015) and Korea Health Technology R&D Project through the Korea Health Industry Development Institute (HI18C2383), funded by the Ministry of Health & Welfare, Republic of Korea. J.M.S.: NIH (1P20RR021938-01). A.R.M.: NIH (P30GM122734, R01MH101512). C.M.D.-C.: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (PI17/00481, PI20/00721, JR19/00024). S. Cervenka: Swedish Research Council (523-2014-3467). M. Kirschner: Swiss National Science Foundation (SNSF) (P2SKP3_178175). T.H.: CIHR (142255), Ministry of Health of the Czech Republic (16-32791A, NU20-04-00393), Brain & Behavior Research Foundation (BBRF) Young and Independent Investigator Awards. A. James: Medical Research Council (MRC) (G0500092). P.H.: NARSAD grant from the BBRF (28445), Research Grant from the Novartis Foundation (20A058). R.C.G.: NIH (1R01MH117014, 1R01MH119219). N.J.: NIH (R01MH117601). S.E.M.: NHMRC (APP1172917). J.A.T.: NIH (R01MH1​21246). Dataset-Specific Funding Sources and Acknowledgments: AMC: Supported by grants from The Netherlands Organisation for Health Research and Development (ZonMw) (3160007, 91676084, 31160003, 31180002, 31000056, 2812412, 100001002, 100002034), the Dutch Research Council (NWO) (90461193, 40007080, 48004004, 40003330), the Amsterdam Brain Imaging Platform, Neuroscience Campus Amsterdam, and the Dutch Brain Foundation. Processing with FreeSurfer was performed on the Dutch e-Science Grid through BiG Grid project and COMMIT project “e-Biobanking with imaging for healthcare,” which are funded by the NWO. ASRB: Australian Schizophrenia Research Bank, supported by the NHMRC (Enabling Grant, 386500), the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation, and the Schizophrenia Research Institute. Chief Investigators for ASRB were S.V.C., P.T.M., B.J.M., U.S., R.J.S., V.J.C., F.A.H., C.P., Assen Jablensky. We thank C.M.L., the ASRB Manager, and acknowledge the help of Jason Bridge for ASRB database queries. CAMH: Datasets were collected and shared with support from the CAMH Foundation and the CIHR. CASSI (Cognitive and Affective Symptoms in Schizophrenia Intervention): Supported by the University of New South Wales School of Psychiatry, the NHMRC (568807), Neuroscience Research Australia, the Schizophrenia Research Institute utilizing infrastructure funding from NSW Ministry of Health, the Macquarie Group Foundation, and the ASRB (see above). CIAM (Cortical Inhibition and Attentional Modulation): The CIAM group (PI: F.M.H.) was supported by the University Research Committee, University of Cape Town; South African National Research Foundation (NRF); South African Medical Research Council (SA MRC). CLING (Clinical Neuroscience Goettingen): Sample data collection partially supported by the Deutsche Forschungsgemeinschaft (DFG) (GR1950/5-1 to O.G.). COBRE (Center for Biomedical Research Excellence): Supported by NIH (R01EB006841, P20GM103472, 5R01MH094524 to V.D.C. and J.A.T. R01AA021771 and P50AA022534 to J.M.S.), and the NSF (1539067). EdinburghEHRS: Funded by the MRC (G9226254, G9825423), the Dr. Mortimer and Theresa Sackler Foundation. EdinburghFunc: Funded by the MRC Clinical Training Fellowship (G84/5699) and Health Foundation Clinician Scientist Fellowship (2268/4295). EdinburghSFMH: Funded by an award from the Translational Medicine Research Collaboration (NS_EU_166), Scottish Enterprise, Pfizer, the Dr. Mortimer and Theresa Sackler Foundation. The University of Edinburgh is a charitable body, registered in Scotland, with registration number SC005336. Is e buidheann carthannais a th’ ann an Oilthigh Dhùn Èideann, clàraichte an Alba, àireamh clàraidh SC005336. EONCKS: Supported by the SA MRC and the New Partnership for Africa’s Development initiative through the Department of Science and Technology of South Africa (#65174). ESO: Supported by the Ministry of Health of the Czech Republic (NU20-04-00393). FBIRN (Function Biomedical Informatics Research Network): Supported by the National Center for Research Resources at the NIH (1 U24 RR021992 (FBIRN) and 1 U24 RR025736-01 (Biomedical Informatics Research Network Coordinating Center; http://www.birncommunity.org)). Data were processed by the UCI High-Performance Computing cluster supported by Joseph Farran (supported by NIMH R01 MH-58262), Harry Mangalam, and Adam Brenner (supported by NIH 5R01 MH61603, 2R01MH058251), and the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH (through grant UL1 TR000153). FBIRN thank Mrs. Liv McMillan for overall study coordination. FOR2107 Marburg: Funded by the DFG, T.T.J.K. (speaker FOR2107; KI588/14-1, KI588/14-2), Axel Krug (KR3822/5-1, KR3822/7-2), I.N. (NE2254/1-2, NE2254/3-1, NE2254/4-1), Carsten Konrad (KO4291/3-1), and A. Jansen (JA1890/7-1, JA1890/7-2). FOR2107 Münster: Funded by the DFG (FOR2107 DA1151/5-1, DA1151/5-2 to U.D.; SFB-TRR58, Projects C09 and Z02 to U.D.) and the Interdisciplinary Center for Clinical Research of the medical faculty of Münster (Dan3/012/17 to U.D.). Frankfurt: MRI was performed at the Frankfurt Brain Imaging Centre, supported by the DFG and the German Ministry for Education and Research (Brain Imaging Center Frankfurt/Main, DLR01GO0203). GAP (Genetics and Psychosis): The GAP dataset represents independent research funded by the National Institute for Health and Care Research (NIHR) Biomedical Research Centre at South London, Maudsley National Health Service (NHS) Foundation Trust, and King’s College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. GIPSI: Supported by “PRISMA U.T” Colciencias Invitación 990 del 3 de Agosto de 2017, Código 111577757629, Contrato 781 de 2017. GROUP: We thank Truda Driesen and Inge Crolla for their coordinating roles in the data collection, as well as the G.R.O.U.P. investigators: R.S.K., Don H. Linszen, Jim van Os, Durk Wiersma, Richard Bruggeman, W.C., L.dH., Lydia Krabbendam, Inez Myin-Germeys. Infrastructure for the GROUP study is funded through the Geestkracht programme of ZonMw (10-000-1001), and matching funds from participating pharmaceutical companies (Lundbeck, AstraZeneca, Eli Lilly, Janssen Cilag) and universities and mental health care organizations (Amsterdam: Academic Psychiatric Centre of the Academic Medical Center and the mental health institutions: GGZ Ingeest, Arkin, Dijk en Duin, GGZ Rivierduinen, Erasmus Medical Centre, GGZ Noord Holland Noord; Groningen: University Medical Center Groningen and the mental health institutions: Lentis, GGZ Friesland, GGZ Drenthe, Dimence, Mediant, GGNet Warnsveld, Yulius Dordrecht and Parnassia psycho-medical center, The Hague; Maastricht: Maastricht University Medical Centre and the mental health institutions: GGzE, GGZ Breburg, GGZ Oost-Brabant, Vincent van Gogh voor Geestelijke Gezondheid, Mondriaan, Virenze riagg, Zuyderland GGZ, MET ggz, Universitair Centrum Sint-Jozef Kortenberg, CAPRI University of Antwerp, PC Ziekeren Sint-Truiden, PZ Sancta Maria Sint-Truiden, GGZ Overpelt, OPZ Rekem; Utrecht: University Medical Center Utrecht and the mental health institutions Altrecht, GGZ Centraal, and Delta). HMS (Homburg Multidiagnosis Study): Sample data collection was supported by a grant of the Competence Network Schizophrenia to O.G. HUBIN (Human Brain Informatics): Supported by the Swedish Research Council (K2015-62X-15077-12-3), 2017-00949, the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, the Knut and Alice Wallenberg Foundation. Huilong: Funded by the National Natural Science Foundation of China (81761128021; 31671145; 81401115; 81401133), Beijing Municipal Science & Technology Commission grant (Z141107002514016), Beijing Natural Science Foundation (7162087), Beijing Municipal Administration of Hospitals Clinical medicine Development of special funding (XMLX201609; zylx201409). IGP: Imaging Genetics in Psychosis study, funded by Project Grants from the NHMRC (APP630471 and APP1081603), and the Macquarie University’s ARC Centre of Excellence in Cognition and its Disorders (CE110001021). This project used participants from the ASRB (see above), using an infrastructure grant from the NSW Ministry of Health. IMH: Supported by research grants from the National Healthcare Group, Singapore (SIG/05004; SIG/05028), and the Singapore Bioimaging Consortium (RP C009/2006) awarded to K.S. KaSP: Supported by the Swedish Research Council (K2015-62X-15077-12-3), and by grants from the Swedish Medical Research Council (2009-7053, 2013-2838, 523-2014-3467), the Swedish Brain Foundation, Åhlén-siftelsen, Svenska Läkaresällskapet, Petrus och Augusta Hedlunds Stiftelse, Torsten Söderbergs Stiftelse, the AstraZeneca-Karolinska Institutet Joint Research Program in Translational Science, Söderbergs Königska Stiftelse, Professor Bror Gadelius Minne, Knut och Alice Wallenbergs stiftelse, the Swedish Federal Government under the LUA/ALF agreement (C.M.S., S. Cervenka), Centre for Psychiatry Research, KID-funding from the Karolinska Institutet. Madrid: Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), cofinanced by ERDF Funds from the European Commission, “A way of making Europe,” CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program (FP7-4-HEALTH-2009-2.2.1-2-241909—Project EU-GEI, FP7-HEALTH-2013-2.2.1-2-603196—Project PSYSCAN, and FP7-HEALTH-2013-2.2.1-2-602478—Project METSY), European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (115916—Project PRISM, and 777394—Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz. MCIC: Supported by the NIH (NIH/NCRR P41RR14075, R01EB005846 to V.D.C.), the Department of Energy (DE-FG02- 99ER62764), the Mind Research Network, the Morphometry BIRN (1U24, RR021382A), the Function BIRN (U24RR021992-01, NIH.NCRR MO1 RR025758-01, NIMH 1RC1MH089257 to V.D.C.), the DFG (research fellowship to S.E.), and a NARSAD Young Investigator Award (to S.E.). MPRC: Support received from NIH (U01MH108148, 2R01EB015611, R01MH112180, R01DA027680, R01MH085646, P50MH103222, and T32MH067533), a State of Maryland contract (M00B6400091), and NSF grant (1620457). OLIN: Supported by NIH (R01MH106324, R01MH077945). Osaka: Partially supported by AMED (JP21dm0307002, JP21dm0207069, JP21dk0307103, JP21uk1024002, and JP21wm0425012), JSPS KAKENHI (JP20H03611, JP20K06920), and Intramural Research Grant (3-1) for Neurological and Psychiatric Disorders of NCNP. Computations were performed using Research Center for Computational Science, Okazaki, Japan. Oxford: We would like to thank the participants and their families, referring psychiatrists, and the Donnington Health Centre, Oxford. This study is supported by the MRC, OHSRC, UK EPSRC, BBSRC, and Wellcome Trust. PAFIP: We wish to thank all PAFIP research teams and all patients and family members who participated in the study. PAFIP has been funded by Instituto de Salud Carlos III through the projects PI14/00639, PI14/00918, and PI17/01056 (cofunded by ERDF/ESF “Investing in your future”), Health Research Institute Marques de Valdecilla (NTC0235832, NCT02534363), Instituto de Salud Carlos III, FIS 00/3095, 01/3129, PI020499, PI060507, PI10/00183, the SENY Fundació Research Grant (CI 2005‐0308007), the Fundación Marqués de Valdecilla (API07/011), MINECOSAF2013-46292-R, PSYSCAN (Exp.: HEALTH.2013.2.2.1-2_Grant agreement no. 603196). We want to particularly acknowledge the patients and the BioBankValdecilla (PT13/0010/0024) integrated in the Spanish National Biobanks Network for its collaboration. We thank IDIVAL Neuroimaging Unit for its help in the technical execution of this work. RSCZ: Supported in part by the RFBR (20-013-00748). SCORE: This study was supported in part by the SNSF (3232BO_119382). We thank the FePsy (Frueherkennung von Psychosen; early detection of psychosis) Study Group from the University of Basel, Department of Psychiatry, Switzerland, for the recruitment of the study participants. The FePsy Study was supported in part by grant no. SNF 3200-057216/1, ext./2, ext./3. SNUH: Supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) and the Korea Brain Research Institute (KBRI) basic research program through the KBRI, funded by the Ministry of Science, ICT & Future Planning (2019R1C1C1002457, 2020M3E5D9079910, 21-BR-03–01). SWIFT: Supported in part by the SNSF (320030_146789). TOP: Supported by the Research Council of Norway (#160181, 190311, 223273, 213837, 249711), the South-East Norway Health Authority (2014114, 2014097, 2017- 112), the Kristian Gerhard Jebsen Stiftelsen (SKGJ‐MED‐008), and the European Community’s Seventh Framework Programme (FP7/2007–2013), grant agreement no. 602450 (IMAGEMEND). UCISZ: Supported by the NIMH (R21MH097196 to T.G.M.v.E.). Data were processed by the UCI High-Performance Computing cluster (see FBIRN). UMCU: Supported by ZonMw (90802123, 91746370 to H.E.H.P., and 10-000-1001 to R.S.K.). UNIBA: Supported by grant funding from the Italian Ministry of Research (2017M7SZM8_004, PI A.B.; 2017K2NEF4, PI G.P.). UNIMAAS: Supported by ZonMw (91112002) and by a personal grant to T.v.A. (ZonMw-VIDI: 91712394). This clinical trial was registered in the Dutch clinical trial registry under ID: NTR5094 (https://trialsearch.who.int/Trial2.aspx?TrialID=NTR5094). Zurich: Funded by the SNSF., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic analysis of intracranial and subcortical brain volumes yields polygenic scores accounting for variation across ancestries

  • García-Marín, Luis M.
  • Campos, Adrian I.
  • Diaz-Torres, Santiago
  • Crespo-Facorro, Benedicto
  • Romero García, Rafael
  • Tordesillas-Gutiérrez, Diana
  • Vázquez-Bourgon, Javier
García-Marín, Luis M.; Campos, Adrian I.; Diaz-Torres, Santiago; et al., Subcortical brain structures are involved in developmental, psychiatric and neurological disorders. Here we performed genome-wide association studies meta-analyses of intracranial and nine subcortical brain volumes (brainstem, caudate nucleus, putamen, hippocampus, globus pallidus, thalamus, nucleus accumbens, amygdala and the ventral diencephalon) in 74,898 participants of European ancestry. We identified 254 independent loci associated with these brain volumes, explaining up to 35% of phenotypic variance. We observed gene expression in specific neural cell types across differentiation time points, including genes involved in intracellular signaling and brain aging-related processes. Polygenic scores for brain volumes showed predictive ability when applied to individuals of diverse ancestries. We observed causal genetic effects of brain volumes with Parkinson's disease and attention-deficit/hyperactivity disorder. Findings implicate specific gene expression patterns in brain development and genetic variants in comorbid neuropsychiatric disorders, which could point to a brain substrate and region of action for risk genes implicated in brain diseases., This project has received funding from the European Union's Horizon 2020 Research and Innovation Programme under the Specific Grant Agreement 945539 (Human Brain Project SGA3). This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643417, No 640643, and No 667375 and 754517. IMAGEN was funded by the European Union-funded FP6 Integrated Project IMAGEN (LSHM-CT- 2007-037286). The MCIC study was supported by the National Institutes of Health (NIH/NCRR P41RR14075 and R01EB005846), the Department of Energy (DE-FG02-99ER62764). NeuroIMAGE also received funding from the European Community’s Seventh Framework Programme (FP7/2007– 2013) under grant agreements n° 602805 (Aggressotype), n° 278948 (TACTICS), and n° 602450 (IMAGEMEND), and from the European Community’s Horizon 2020 Programme (H2020/2014– 2020) under grantagreements n°643051(MiND), n° 667302 (CoCA), and n° 728018 (Eat2beNICE). Additional support is received from the European Community's Seventh Framework Programme (FP7/2007– 2013) under grant agreements nº 602805 (Aggressotype), nº 603016 (MATRICS), nº 602450 (IMAGEMEND), and nº 278948 (TACTICS), and from the European Community's Horizon 2020 Programme (H2020/2014– 2020) under grant agreements nº 643051 (MiND) and nº 667302(CoCA). Erasmus Rucphen family study (ERF): The ERF study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no.QLG2-CT-2002-01254). the European Science Foundation (ESF, EU/QLRT-2001-01254), the European Community’s Seventh Framework Programme (FP7- HEALTH-F4-2007-2013, grant 01413: ENGAGE and grant 602768: ACTION); the European Research Council (ERC Starting 284167, ERC Consolidator 771057, ERC Advanced 230374). The Horizon 2020 supported programme CANDY Grant No. 847818). European Community’s Horizon 2020 Programme (H2020/2014– 2020) under grant agreement n° 847879 (PRIME). European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG, Grant 802998). This work was supported by Fundación Marqués de Valdecilla, Instituto de investigación sanitaria Valdecilla., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Penetrance of neurodevelopmental copy number variants is associated with variations in cortical morphology

  • Silva, Ana I.
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
  • Linden, David E. J.
  • ENIGMA-CNV Working Group
ENIGMA-CNV Working Group: et al, [Background] Copy number variants (CNVs) may increase the risk for neurodevelopmental conditions. The neurobiological mechanisms that link these high-risk genetic variants to clinical phenotypes are largely unknown. An important question is whether brain abnormalities in individuals who carry CNVs are associated with their degree of penetrance., [Methods] We investigated whether increased CNV penetrance for schizophrenia and other developmental disorders was associated with variations in cortical and subcortical morphology. We pooled T1-weighted brain magnetic resonance imaging and genetic data from 22 cohorts from the ENIGMA (Enhancing Neuro Imaging Genetics through Meta Analysis)-CNV consortium. In the main analyses, we included 9268 individuals (aged 7–90 years, 54% female), from which we identified 398 carriers of 36 neurodevelopmental CNVs at 20 distinct loci. A secondary analysis was performed including additional neuroimaging data from the ENIGMA-22q consortium, including 274 carriers of the 22q11.2 deletion and 291 noncarriers. CNV penetrance was estimated through penetrance scores that were previously generated from large cohorts of patients and controls. These scores represent the probability risk of developing either schizophrenia or other developmental disorders (including developmental delay, autism spectrum disorder, and congenital malformations)., [Results] For both schizophrenia and developmental disorders, increased penetrance scores were associated with lower surface area in the cerebral cortex and lower intracranial volume. For both conditions, associations between CNV-penetrance scores and cortical surface area were strongest in regions of the occipital lobes, specifically in the cuneus and lingual gyrus., [Conclusions] Our findings link global and regional cortical morphometric features with CNV penetrance, providing new insights into neurobiological mechanisms of genetic risk for schizophrenia and other developmental disorders., 16p11.2 Consortium: This work was supported by Compute Canada, the Brain Canada Multi investigator research initiative, Canada First Research Excellence Fund, the Institute of Data Valorization, and Healthy Brain Healthy Lives. SJ is a recipient of a Canada Research Chair in neurodevelopmental disorders and a chair from the Jeanne et Jean Louis Levesque Foundation. This work was supported by the Canadian Institutes of Health Research (CIHR) (Grant Nos. 400528 and 438531) and Innovative Medicines Initiative 2 Joint Undertaking (Grant No. 777394) for AIMS-2-TRIALS. This Joint Undertaking receives support from the EU’s Horizon 2020 program, EFPIA, Autism Speaks, Autistica, and SFARI. KK was supported by The Institute of Data Valorization Postdoctoral Fellowship program, through the Canada First Research Excellence Fund. COBRE (Centers of Biomedical Research Excellence): This research is funded by National Science Foundation (Grant No. 2112455) and National Institutes of Health (NIH) (Grant No. R01MH118695). Dublin: This research is funded by European Research Council (Grant No. 677467). ECHO-DEFINE: The ECHO (Experiences of Children with Copy Number Variants) study acknowledges funding from the Wellcome Trust (Institutional Strategic Support Fund) (to MBMvdB) and Clinical Research Training Fellowship (Grant No. 102003/Z/13/Z [to JLD]), the Waterloo Foundation (Grant No. WF 918- 1234 [to MBMvdB]), the Baily Thomas Charitable Fund (Grant No. 2315/1 [to MBMvdB]), National Institute of Mental Health (NIMH) (Grant No. 5UO1MH101724) and NIMH (Grant No. U01MH119738 [to MBMvdB]), the IMAGINE-ID and IMAGINE-2 studies (funded by Medical Research Council [MRC]) (Grant Nos. MR/N022572/1 and MR/T033045/1 [to MBMvdB]) and an MRC Centre Grant (Grant No. MR/P005748/1 [to MJO]). The DEFINE (Defining Endophenotypes From Integrative Neuroscience) study was supported by a Wellcome Trust Strategic Award (Grant No. 100202/Z/12/Z [to MJO]). ENIGMA: The ENIGMA Working Group acknowledges the NIH Big Data to Knowledge award for foundational support and consortium development (Grant No. U54 EB020403 [to PMT]). For a complete list of ENIGMA-related grant support, please see here: http://enigma.ini.usc.edu/about-2/funding/. PMT and SIT are also supported in part by ENIGMA NIH (Grant Nos. R01MH116147, R01NS107513, R01AG058854, and R01MH129742). IES is supported by the Research Council of Norway (Grant No. 223273), South-Eastern Norway Regional Health Authority (Grant No. 2020060), European Union’s Horizon2020 Research and Innovation Programme (CoMorMent project) (Grant No. 847776), and Kristian Gerhard Jebsen Stiftelsen (Grant No. SKGJ-MED-021). South-Eastern Norway Regional Health Authority (Grant No. 2020060) also supports RBo. This work was partially performed on Services for Sensitive Data (TSD), University of Oslo, Norway, with resources provided by UNINETT Sigma2, the National Infrastructure for High Performance Computing and Data Storage in Norway. OAA is supported by Research Council of Norway (Grant No. 223273) and KG Jebsen Stiftelsen (Grant No. SKGJ-MED-021). NJ is supported by NIH (Grant No. R01MH117601). DvdM is supported by Research Council of Norway (Grant No. 276082). ENIGMA-22q: This research is supported by NIMH (Grant Nos. R01MH085953, R21MH116473, and 9U01MH119736-02). ASB is supported by the Dalglish Family Chair in 22q11.2 Deletion Syndrome, CIHR (Grant Nos. MOP-79518, MOP-89066, MOP-97800, and MOP-111238) and NIMH (Grant No. U01MH101723–01[3/5]). EWCC acknowledges support from the CIHR (Grant No. MOP-74631) and Ontario Mental Health Foundation for the current work. DRR is supported by NIMH (Grant No. R01 119185). JES is supported by the Stanford Maternal and Child Health Research Institute Uytengsu-Hamilton 22q11 Neuropsychiatry Research Awards Program (Grant No. UH22QEXTFY21). DMM-M acknowledges support from NIMH (Grant No. U01MH119737). JASV acknowledges funding support from NIMH (Grant Nos. 1U01MH119741-01 and 3U01MH119741-02S1). TvA acknowledges financial support from NIMH (Grant No. 5U01 MH119740). GAP: PD’s research is supported by the MRC and the Wellcome Trust. Funding was received from the Psychiatry Research Trust, the Wellcome Trust, the MRC, and the National Institute for Health Research (NIHR) Biomedical Research Centre at the South London and Maudsley NHS Trust. The funding sources were not involved in carrying out or interpreting the study. GOBS: The GOBS (Genetics of Brain Structure and Function study) data collection was supported in part by NIH (Grant Nos. R01MH078143 and R01MH083824). Haavik: This research is supported by Stiftelsen KG Jebsen (Grant No. SKGJ MED-02), the Research Council of Norway, and Helse Vest RHF. HUBIN (Human Brain Informatics): This research is supported by Swedish Research Council (Grant Nos. K2007-62X-15077-04-1, K2008-62P-20597-01-3, K2010-62X-15078-07-2, K2012-61X-15078-09-3, K2015-62X-15077-12-3, and 2017-00949), the regional agreement on medical training and clinical research between Stockholm County Council and the Karolinska Institutet, and the Research Council of Norway (Grant No. 274 359). HUNT: The HUNT (Trøndelag Health Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology), North Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health. HUNT-MRI was funded by the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology and the Norwegian National Advisory Unit for functional MRI. IMAGEN: The European Union–funded FP6 Integrated Project IMAGEN (Reinforcement-related behavior in normal brain function and psychopathology) (Grant No. LSHM-CT- 2007-037286), the Horizon 2020 funded ERC Advanced Grant STRATIFY (Brain network based stratification of reinforcement-related disorders) (Grant No. 695313), Human Brain Project (Grant Nos. HBP SGA 2, 785907, and HBP SGA 3, 945539), the MRC Grant c-VEDA (Consortium on Vulnerability to Externalizing Disorders and Addictions) (Grant No. MR/N000390/1), NIH (Grant No. R01DA049238), A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, the Bundesministerium für Bildung und Forschung (Grant Nos. 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC- Mind 01GL1745B), the Deutsche Forschungsgemeinschaft (DFG Grant Nos. SM 80/7-2, SFB 940, TRR 265, NE 1383/14-1), ImagenPathways “Understanding the Interplay between Cultural, Biological and Subjective Factors in Drug Use Pathways” is a collaborative project supported by the European Research Area Network on Illicit Drugs, the Medical Research Foundation and MRC (Grant Nos. MR/R00465X/1 and MR/S020306/1), the NIH-funded ENIGMA (Grant Nos. 5U54EB020403-05 and 1R56AG058854-01), National Natural Science Foundation of China (NSFC) (Grant No. 82 150 710 554), and European Union–funded project environMENTAL (Grant No. 101057429). Additional support was provided by grants from the ANR (Grant Nos. ANR-12-SAMA-0004, AAPG2019—GeBra), the Eranet Neuron (Grant Nos. AF12-NEUR0008-01—WM2NA; and ANR-18-NEUR00002-01—ADORe), the Fondation de France (Grant No. 00081242), the Fondation pour la Recherche Médicale (Grant No. DPA20140629802), the Mission Interministérielle de Lutte-contre-les-Drogues-et-les-Conduites-Addictives, the Assistance Publique-Hôpitaux de Paris and Institut National de la Santé et de la Recherche Médicale (INSERM) (interface grant), Paris Sud University IDEX 2012, the Fondation de l’Avenir (Grant No. AP-RM-17-013), the Fédération pour la Recherche sur le Cerveau; the NIH, Science Foundation Ireland (Grant No. 16/ERCD/3797), the Science Foundation Ireland (Grant No. 16/ERCD/3797), the NIH (Axon, Testosterone and Mental Health during Adolescence) (Grant No. R01MH085772-01A1), and the NIH Consortium (Grant No. U54 EB020403), supported by a cross-NIH alliance that funds Big Data to Knowledge Centres of Excellence. The INSERM, the Strasbourg University, and SATT CONECTUS, provided sponsorship (principal investigator: J-LM). TP is supported by NIH (Grant No. R01MH085772). Gilles Berstchy is acknowledged for his support. Stephane Lehericy and the radiographer staff at Centre de NeuroImagerie de Recherche de l'’Institut du Cerveau (http://www.cenir.org/mri.html?lang=en) are acknowledged for their support in acquisition of MRI datasets. MCIC (Mind Clinical Imaging Consortium): This research is funded by NIH study P20GM103472. METH-CT: DJS is supported by the South African Medical Research Council (SAMRC). FS is supported by a PDRF (Presidential Doctoral Research Fellowship) from the Brain Behavior Unit, Department of Psychiatry and Mental Health, University of Cape Town. SD is supported by the Biomedical Research and Innovation Platform and SAMRC. NCNG: NCNG (Norwegian Cognitive NeuroGenetics sample) was supported by the Bergen Research Foundation, the University of Bergen, the Research Council of Norway (FUGE) (Enhance Research in Functional Genomics) (Grant Nos. 151904 and 183327), Psykisk Helse (Grant No. 175345), RCN (Grant Nos. 154313/V50 [to Ivar Reinvang] and 177458/V50 [to TE]), Helse SørØst RHF (Grant No. 2012086 [to TE]), and the Dr. Einar Martens Fund. NTR: The NTR cohort was supported by the Netherlands Organization for Scientific Research (NWO) and The Netherlands Organization for Health Research and Development (ZonMW) (Grant Nos. 904-61-090, 985-10-002, 912-10-020, 904-61-193, 480-04-004, 463-06-001, 451-04-034, 400-05-717, Addiction-31160008, 016-115-035, 481-08-011, 400-07-080, 056-32-010, Middelgroot-911-09-032, OCW_NWO Gravity program –024.001.003, NWO-Groot 480-15-001/674), Center for Medical Systems Biology (CMSB, NWO Genomics), NBIC/BioAssist/RK(2008.024), Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) (Grant Nos. NL, 184.021.007 and 184.033.111), X-Omics 184-034-019; Spinozapremie (Grant No. NWO- 56-464-14192), KNAW Academy Professor Award (PAH/6635) and University Research Fellow grant (to DIB); Amsterdam Public Health Research Institute (former EMGO+), Neuroscience Amsterdam research institute (former NCA); the European Community’s Fifth and Seventh Framework Program (Grant Nos. FP5- LIFE QUALITY-CT-2002-2006, FP7-HEALTH-F4-2007-2013, Grant No. 01254: GenomEUtwin, Grant No. 01413: ENGAGE and Grant No. 602768:ACTION); the European Research Council (Grant Nos. ERC Starting 284 167, ERC Consolidator 771057, ERC Advanced 230374), Rutgers University Cell and DNA Repository (NIMH) (Grant No. U24 MH068457-06), NIH (Grant Nos. R01D0042157-01A1, R01MH58799-03, MH081802, DA018673, R01DK092127-04), Grand Opportunity (Grant Nos. 1RC2 MH089951 and 1RC2 MH089995); and the Avera Institute for Human Genetics, Sioux Falls, South Dakota. Part of the genotyping and analyses were funded by the Genetic Association Information Network of the Foundation for the NIH. Computing was supported by NWO (Grant No. 2018/EW/00408559), BiG Grid, the Dutch e-Science Grid, and SURFSARA. OATS1/OATS2 and Sydney MAS: The OATS (Older Australian Twins Study) has been funded by a National Health & Medical Research Council (NHMRC) and Australian Research Council (ARC) Strategic Award Grant of the Ageing Well, Ageing Productively Program (Grant No. 401162); NHMRC Project (seed) Grants (Grant Nos. 1024224 and 1 025 243); NHMRC Project Grants (Grant Nos. 1045325 and 1085606); and NHMRC Program Grants (Grant Nos. 568969 and 1093083). This research was facilitated through access to Twins Research Australia, which is a national resource supported by a Centre of Research Excellence Grant (Grant No. 1079102) from the NHMRC. The Sydney Memory and Ageing Study has been funded by 3 NHMRC Program Grants (Grant Nos. ID350833, ID568969, and APP1093083). Core funding was received from the NSW Government Department of Health and the Australian government Department of Health and Aged Care; NHMRC Leadership Fellowship (Grant No. GNT2009771); NHMRC (Grant No. GNT1045325). DNA samples were extracted by Genetic Repositories Australia, an Enabling Facility, which was supported by an NHMRC Grant (Grant No. 401184). MRI scans were processed with the support of NHMRC Project Grants (Grant Nos. 510175 and 1025243) and an ARC Discovery Project Grant (Grant No. DP0774213) and John Holden Family Foundation. PAFIP: This study was supported by grants from Carlos III Health Institute (Grant Nos. IPI17/00402, PI17/01056, PI14/00639, and PI14/00918) cofunded by the European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (Grant Nos. NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. JV-B acknowledges IDIVAL Grants (Grant Nos. INT/A21/10 and INT/A20/04). QTIM: The QTIM study was supported by grants from the U.S. National Institute of Child Health and Human Development (Grant No. R01HD050735) and the Australian NHMRC (Grant Nos. 486682, 1009064). Genotyping was supported by NHMRC (Grant No. 389875). AFM is funded by an ARC Future Fellowship (Grant No. FT200100837). SEM is supported by NHMRC Investigator Grant (Grant No. APP1172917). SHIP-2/SHIP-TREND: SHIP is part of the Community Medicine Research net of the University of Greifswald, Germany, which is funded by the Federal Ministry of Education and Research (Grant Nos. 01ZZ9603, 01ZZ0103, and 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania, and the network “Greifswald Approach to Individualized Medicine (GANI_MED)” funded by the Federal Ministry of Education and Research (Grant No. 03IS2061A). Genome-wide data have been supported by the Federal Ministry of Education and Research (Grant No. 03ZIK012) and a joint grant from Siemens Healthineers and the Federal State of Mecklenburg-West Pomerania. The University of Greifswald is a member of the Caché Campus program of the InterSystems GmbH. This study has received funding from the following institutions: Federal Ministry of Education and Research, the Ministry of Cultural Affairs, as well as the Social Ministry of the Federal State of Mecklenburg-West Pomerania. MRI examinations were supported by Siemens Healthineers, Siemens Healthcare GmbH. AT has been funded by DFG (Grant No. 542489987). The SHIP authors thank Holger Prokisch and Thomas Meitinger (Helmholtz Zentrum München) for the genotyping of the SHIP-TREND cohort. Stroke (TOP_T3): The European Research Council under the European Union’s Horizon 2020 research and Innovation program (Grant No. ERC 802998). The Research Council of Norway (Grant Nos. 298646 and 300767), and the South-Eastern Norway Regional Health Authority (Grant Nos. 2013054, 2015044, 2015073, 2018076, 2019101, and 2020060)., Peer reviewed